Healthcare platform Sesame announced a new weight loss program offering compounded versions of Novo Nordisk A/S's (NYSE:NVO) blockbuster drug Wegovy for $249 per month.
The program aims to make obesity and diabetes treatments more accessible, addressing supply shortages of popular medications like Wegovy and Ozempic by providing lower-cost compounded semaglutide, the active ingredient in these drugs.
Also Read: Ozempic And Wegovy Linked to Increased Suicidal Thoughts In Observational Study, But Results Are Contested.
The company's platform allows patients to book and pay for appointments directly with doctors and specialists, bypassing insurers. Sesame already offers branded weight loss and diabetes treatments, including through a partnership with Costco Wholesale Corporation (NASDAQ:COST).
However, the introduction of compounded medications provides a more affordable alternative, given that brand-name drugs like Wegovy and Ozempic can cost around $1,000 per month before insurance coverage.
Supply shortages have become a critical challenge for Novo Nordisk and Eli Lilly And Co (NYSE:LLY), leading to the offering of compounded versions when brand-name supplies dwindle.
Compounded medications, tailored to individual patient needs, are governed under specific FDA regulations.
The CNBC report added that Sesame has partnered with a 503B compounding pharmacy that produces prefilled, single-use syringes, a move designed to reduce risks associated with improper dosing.
Michael Botta, president and co-founder of Sesame, told CNBC in an interview that Sesame initially hesitated to offer compounded medications due to concerns about quality, but after inspecting the processes of its pharmacy partner, the company became confident in the safety and effectiveness of the treatments.
Price Action: NVO stock is down 1.26% at $134.10 at last check Wednesday.
- Eli Lilly's Famed Obesity/Diabetes Treatment Tirzepatide Shows Potential To Cut Risk Of Developing Diabetes, Sustained Weight Loss Over 3 Years.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo:Tobias Arhelger/Shutterstock.com
醫療保健平台Sesame宣佈了一項新的減肥計劃，以每月249美元的價格提供諾和諾德A/S（紐約證券交易所代碼：NVO）重磅藥物Wegovy的複合版本。
該計劃旨在通過提供低成本的複合索瑪魯肽（Wegovy和Ozempic等藥物中的活性成分）來解決肥胖和糖尿病治療更容易獲得的治療，解決這些藥物的供應短缺問題。
另請閱讀：在觀察性研究中，Ozempic和Wegovy與自殺念頭增加有關，但結果存在爭議。
該公司的平台允許患者繞過保險公司，直接與醫生和專家預約和支付預約費用。Sesame已經提供品牌減肥和糖尿病治療，包括通過與好市多批發公司（納斯達克股票代碼：COST）的合作。
但是，鑑於Wegovy和Ozempic等名牌藥物在投保前每月的費用約爲1,000美元，複合藥物的推出提供了一種更實惠的替代方案。
供應短缺已成爲Novo Nordisk和Eli Lilly And Co（紐約證券交易所代碼：LLY）面臨的嚴峻挑戰，當名牌供應減少時，他們會推出複合版本。
根據患者個人需求量身定製的複合藥物受美國食品藥品管理局的特定法規管轄。
CNBC的報告補充說，Sesame已與一家生產預充一次性注射器的5030複合藥房合作，此舉旨在降低與劑量不當相關的風險。
Sesame總裁兼聯合創始人邁克爾·博塔在接受CNBC採訪時告訴CNBC，由於擔心質量，Sesame最初對提供複合藥物猶豫不決，但在檢查了其藥房合作伙伴的流程後，該公司對治療的安全性和有效性產生了信心。
價格走勢：週三最後一次檢查時，NVO股價下跌1.26％，至134.10美元。
- 禮來公司著名的肥胖/糖尿病治療藥物替西帕肽顯示出降低患糖尿病風險的潛力，在3年內持續減肥。
免責聲明：此內容部分是在人工智能工具的幫助下製作的，並由Benzinga的編輯審閱和發佈。
照片：Tobias arhelger/Shutterstock.com
